- Report
- September 2026
- 186 Pages
Global
From €3227EUR$3,545USD£2,777GBP
€3586EUR$3,939USD£3,086GBP
- Report
- September 2026
- 195 Pages
Global
From €3227EUR$3,545USD£2,777GBP
€3586EUR$3,939USD£3,086GBP
- Report
- September 2026
- 199 Pages
Global
From €3227EUR$3,545USD£2,777GBP
€3586EUR$3,939USD£3,086GBP
- Report
- September 2026
- 181 Pages
Global
From €3227EUR$3,545USD£2,777GBP
€3586EUR$3,939USD£3,086GBP
- Report
- September 2026
- 197 Pages
Global
From €5325EUR$5,850USD£4,583GBP
- Report
- February 2026
- 250 Pages
Global
From €4087EUR$4,490USD£3,517GBP
- Report
- February 2026
- 250 Pages
Global
From €4087EUR$4,490USD£3,517GBP
- Report
- February 2026
- 250 Pages
Global
From €4087EUR$4,490USD£3,517GBP
- Report
- February 2026
- 250 Pages
Global
From €4087EUR$4,490USD£3,517GBP
- Report
- February 2026
- 250 Pages
Global
From €4087EUR$4,490USD£3,517GBP
- Report
- February 2026
- 250 Pages
Global
From €4087EUR$4,490USD£3,517GBP
- Report
- February 2026
- 250 Pages
Global
From €4087EUR$4,490USD£3,517GBP
- Report
- May 2026
- 185 Pages
Global
From €4096EUR$4,500USD£3,525GBP
- Report
- February 2026
- 250 Pages
Global
From €4087EUR$4,490USD£3,517GBP
- Drug Pipelines
- September 2026
- 150 Pages
Global
From €3413EUR$3,750USD£2,938GBP
- Report
- December 2025
- 200 Pages
Global
From €7237EUR$7,950USD£6,228GBP
- Report
- July 2026
- 160 Pages
Global
From €4324EUR$4,750USD£3,721GBP
- Report
- May 2026
- 400 Pages
Global
From €4505EUR$4,949USD£3,877GBP
- Report
- August 2026
- 160 Pages
Global
From €3022EUR$3,320USD£2,601GBP
€3778EUR$4,150USD£3,251GBP
- Report
- August 2026
- 70 Pages
Europe
From €4324EUR$4,750USD£3,721GBP

Alpha Glucosidase Inhibitors are a class of drugs used to treat Endocrine and Metabolic Disorders. These drugs work by inhibiting the enzyme alpha-glucosidase, which is responsible for breaking down carbohydrates in the small intestine. This helps to reduce the amount of glucose absorbed into the bloodstream, which can help to control blood sugar levels. Alpha Glucosidase Inhibitors are commonly used to treat type 2 diabetes, as well as other conditions such as polycystic ovary syndrome and gestational diabetes.
Alpha Glucosidase Inhibitors are available in both oral and injectable forms. Common side effects of these drugs include abdominal pain, nausea, and diarrhea. Long-term use of these drugs can also lead to an increased risk of hypoglycemia.
Some companies that produce Alpha Glucosidase Inhibitors include Novo Nordisk, Sanofi, Eli Lilly, and Merck. Show Less Read more